Serum Androstenedione and Testosterone After Single Doses of NBI-77860, Mean, and Percent Change From Placebo During the Morning Window (6–10 am)
| Participant . | Dose . | Androstenedione . | Testosterone . | ||
|---|---|---|---|---|---|
| Mean (ng/dl) . | % Change From Placebo . | Mean (ng/dl) . | % Change From Placebo . | ||
| 1011001 | Placebo | 303.0 | 0 | 105.3 | 0 |
| 300 | 295.3 | −2.5 | 131.7 | 25.0 | |
| 600 | 265.7 | −12.3 | 122.7 | 16.5 | |
| 1011002 | Placebo | 185.3 | 0 | 49.7 | 0 |
| 300 | 190.7 | 2.9 | 42.7 | −14.1 | |
| 600 | 78.0 | −57.9 | 23.0 | −53.7 | |
| 1011003 | Placebo | 146.0 | 0 | 35.0 | 0 |
| 300 | 132.7 | −9.1 | 32.3 | −7.6 | |
| 600 | 147.7 | 1.1 | 34.0 | −2.9 | |
| 1011004 | Placebo | 820.0 | 0 | 169.3 | 0 |
| 300 | 747.7 | −8.8 | 158.7 | −6.3 | |
| 600 | 934.0 | 13.9 | 164.0 | −3.1 | |
| 1011005 | Placebo | 308.0 | 0 | 76.3 | 0 |
| 300 | 377.0 | 22.4 | 107.3 | 40.6 | |
| 600 | 420.3 | 36.5 | 83.0 | 8.7 | |
| 1011006 | Placebo | 195.7 | 0 | 59.7 | 0 |
| 300 | 141.0 | −27.9 | 36.7 | −38.5 | |
| 600 | 173.3 | −11.4 | 50.7 | −15.1 | |
| 1011007 | Placebo | 145.3 | 0 | 47.3 | 0 |
| 300 | 135.3 | −6.9 | 32.3 | −31.7 | |
| 600 | 84.7 | −41.7 | 19.0 | −59.9 | |
| 1011008 | Placebo | 914.0 | 0 | 127.0 | 0 |
| 300 | 973.3 | 6.5 | 147.3 | 16.0 | |
| 600 | 1366.3 | 49.5 | 194.3 | 53.0 | |
| Participant . | Dose . | Androstenedione . | Testosterone . | ||
|---|---|---|---|---|---|
| Mean (ng/dl) . | % Change From Placebo . | Mean (ng/dl) . | % Change From Placebo . | ||
| 1011001 | Placebo | 303.0 | 0 | 105.3 | 0 |
| 300 | 295.3 | −2.5 | 131.7 | 25.0 | |
| 600 | 265.7 | −12.3 | 122.7 | 16.5 | |
| 1011002 | Placebo | 185.3 | 0 | 49.7 | 0 |
| 300 | 190.7 | 2.9 | 42.7 | −14.1 | |
| 600 | 78.0 | −57.9 | 23.0 | −53.7 | |
| 1011003 | Placebo | 146.0 | 0 | 35.0 | 0 |
| 300 | 132.7 | −9.1 | 32.3 | −7.6 | |
| 600 | 147.7 | 1.1 | 34.0 | −2.9 | |
| 1011004 | Placebo | 820.0 | 0 | 169.3 | 0 |
| 300 | 747.7 | −8.8 | 158.7 | −6.3 | |
| 600 | 934.0 | 13.9 | 164.0 | −3.1 | |
| 1011005 | Placebo | 308.0 | 0 | 76.3 | 0 |
| 300 | 377.0 | 22.4 | 107.3 | 40.6 | |
| 600 | 420.3 | 36.5 | 83.0 | 8.7 | |
| 1011006 | Placebo | 195.7 | 0 | 59.7 | 0 |
| 300 | 141.0 | −27.9 | 36.7 | −38.5 | |
| 600 | 173.3 | −11.4 | 50.7 | −15.1 | |
| 1011007 | Placebo | 145.3 | 0 | 47.3 | 0 |
| 300 | 135.3 | −6.9 | 32.3 | −31.7 | |
| 600 | 84.7 | −41.7 | 19.0 | −59.9 | |
| 1011008 | Placebo | 914.0 | 0 | 127.0 | 0 |
| 300 | 973.3 | 6.5 | 147.3 | 16.0 | |
| 600 | 1366.3 | 49.5 | 194.3 | 53.0 | |
Serum Androstenedione and Testosterone After Single Doses of NBI-77860, Mean, and Percent Change From Placebo During the Morning Window (6–10 am)
| Participant . | Dose . | Androstenedione . | Testosterone . | ||
|---|---|---|---|---|---|
| Mean (ng/dl) . | % Change From Placebo . | Mean (ng/dl) . | % Change From Placebo . | ||
| 1011001 | Placebo | 303.0 | 0 | 105.3 | 0 |
| 300 | 295.3 | −2.5 | 131.7 | 25.0 | |
| 600 | 265.7 | −12.3 | 122.7 | 16.5 | |
| 1011002 | Placebo | 185.3 | 0 | 49.7 | 0 |
| 300 | 190.7 | 2.9 | 42.7 | −14.1 | |
| 600 | 78.0 | −57.9 | 23.0 | −53.7 | |
| 1011003 | Placebo | 146.0 | 0 | 35.0 | 0 |
| 300 | 132.7 | −9.1 | 32.3 | −7.6 | |
| 600 | 147.7 | 1.1 | 34.0 | −2.9 | |
| 1011004 | Placebo | 820.0 | 0 | 169.3 | 0 |
| 300 | 747.7 | −8.8 | 158.7 | −6.3 | |
| 600 | 934.0 | 13.9 | 164.0 | −3.1 | |
| 1011005 | Placebo | 308.0 | 0 | 76.3 | 0 |
| 300 | 377.0 | 22.4 | 107.3 | 40.6 | |
| 600 | 420.3 | 36.5 | 83.0 | 8.7 | |
| 1011006 | Placebo | 195.7 | 0 | 59.7 | 0 |
| 300 | 141.0 | −27.9 | 36.7 | −38.5 | |
| 600 | 173.3 | −11.4 | 50.7 | −15.1 | |
| 1011007 | Placebo | 145.3 | 0 | 47.3 | 0 |
| 300 | 135.3 | −6.9 | 32.3 | −31.7 | |
| 600 | 84.7 | −41.7 | 19.0 | −59.9 | |
| 1011008 | Placebo | 914.0 | 0 | 127.0 | 0 |
| 300 | 973.3 | 6.5 | 147.3 | 16.0 | |
| 600 | 1366.3 | 49.5 | 194.3 | 53.0 | |
| Participant . | Dose . | Androstenedione . | Testosterone . | ||
|---|---|---|---|---|---|
| Mean (ng/dl) . | % Change From Placebo . | Mean (ng/dl) . | % Change From Placebo . | ||
| 1011001 | Placebo | 303.0 | 0 | 105.3 | 0 |
| 300 | 295.3 | −2.5 | 131.7 | 25.0 | |
| 600 | 265.7 | −12.3 | 122.7 | 16.5 | |
| 1011002 | Placebo | 185.3 | 0 | 49.7 | 0 |
| 300 | 190.7 | 2.9 | 42.7 | −14.1 | |
| 600 | 78.0 | −57.9 | 23.0 | −53.7 | |
| 1011003 | Placebo | 146.0 | 0 | 35.0 | 0 |
| 300 | 132.7 | −9.1 | 32.3 | −7.6 | |
| 600 | 147.7 | 1.1 | 34.0 | −2.9 | |
| 1011004 | Placebo | 820.0 | 0 | 169.3 | 0 |
| 300 | 747.7 | −8.8 | 158.7 | −6.3 | |
| 600 | 934.0 | 13.9 | 164.0 | −3.1 | |
| 1011005 | Placebo | 308.0 | 0 | 76.3 | 0 |
| 300 | 377.0 | 22.4 | 107.3 | 40.6 | |
| 600 | 420.3 | 36.5 | 83.0 | 8.7 | |
| 1011006 | Placebo | 195.7 | 0 | 59.7 | 0 |
| 300 | 141.0 | −27.9 | 36.7 | −38.5 | |
| 600 | 173.3 | −11.4 | 50.7 | −15.1 | |
| 1011007 | Placebo | 145.3 | 0 | 47.3 | 0 |
| 300 | 135.3 | −6.9 | 32.3 | −31.7 | |
| 600 | 84.7 | −41.7 | 19.0 | −59.9 | |
| 1011008 | Placebo | 914.0 | 0 | 127.0 | 0 |
| 300 | 973.3 | 6.5 | 147.3 | 16.0 | |
| 600 | 1366.3 | 49.5 | 194.3 | 53.0 | |
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
